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Preface 
The present thesis is based on the work done at the Laboratory of Experimental and 
Clinical Pharmacology, Centre for Sensory-Motor Interaction (SMI); Laboratory for Cancer Biology 
(LCB), Biomedicine, Aalborg University, Denmark; Department of Neurology, Aalborg University 
Hospital and Orthopedic Surgery Research Unit, Aalborg Hospital Science and Innovation Centre, 
Aalborg University Hospital, from January 2011 to August 2014. This thesis is based on three 
performed studies that are referred as Study I, II and III. These studies also yielded three original 
full-length papers that are either published or submitted to relevant international peer-reviewed 
journals. In addition, four conference abstracts, presented as posters in pain scientific meetings 
complement the scientific work conducted in this Ph.D. project.  
 
 Paper I: da Silva LB, Kulas D, Karshenas A, Cairns BE, Bach FW, Arendt-Nielsen L, 
Gazerani P. Time course analysis of the effects of botulinum neurotoxin type A on 
pain and vasomotor responses evoked by glutamate injection into human temporalis 
muscles. Toxins. 2014;6(2):592-607. 
 Paper II: da Silva LB, Karshenas A, Bach FW, Rasmussen S, Arendt-Nielsen L, Gazerani 
P. Blockade of glutamate release by botulinum neurotoxin type A in humans: a 
dermal microdialysis study. Pain Research & Management. 2014;19(3):126-132. 
 Paper III: da Silva LB, Poulsen JN, Arendt-Nielsen L, Gazerani P. Botulinum neurotoxin 
type A modulates calcium-dependent vesicular release of glutamate from trigeminal 
satellite glial cells. Accepted to the Journal of Cellular and Molecular Medicine. 2014. 
 Abstract I: da Silva LB, Kulas D, Karshenas A, Cairns BE, Bach FW, Arendt-Nielsen L, 
Gazerani P. Time-course of analgesic effects of botulinum neurotoxin type A (BoNTA) 
on human experimental model of pain induced by injection of glutamate into 
temporalis muscle. Scandinavian Journal of Pain. 2012;3(3):187, No. T7.  
 Abstract II: da Silva LB, Kulas D, Karshenas A, Cairns BE, Bach FW, Arendt-Nielsen L, 
Gazerani P. Pain, sensitization, and vasomotor responses following intramuscular 
administration of glutamate into temporalis muscle in healthy men and women. In 
Abstracts of the 14th World Congress on Pain, International Association for the Study of 
Pain, IASP, 27-31 August 2012, Milan, Italy. International Association for the Study of Pain, 
IASP. 2012. p. No. PF 426. 
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 Abstract III: da Silva LB, Karshenas A, Rasmussen S, Bach FW, Arendt-Nielsen L, Gazerani 
P. Blockade of glutamate release by botulinum neurotoxin type A in a human 
experimental pain model: a dermal microdialysis study. In Abstract Book of the 8th 
Congress of the European Federation of IASP Chapters (EFIC), 9-12 October 2013, 
Florence, Italy. European Pain Federation EFIC. 2013. p. No. 444. 
 Abstract IV: da Silva LB, Poulsen JN, Arendt-Nielsen L, Gazerani P. Effect of botulinum 
neurotoxin type A on vesicular release of glutamate from trigeminal satellite glial 
cells. In 15th World Congress on Pain, 6-11 October 2014, Buenos Aires, Argentina. 
International Association for the Study of Pain/IASP Press. 2014. p. No. PF036. 
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Summary 
Despite advances in pain treatment, many patients do not achieve optimal pain relief or experience 
significant side effects from current medications. Botulinum neurotoxin type A (BoNTA) is a 
compound that has long been used for patients seeking muscle relaxation due to neuromuscular 
disorders and excess of muscle tension. In these patients, an additional pain relief effect was 
observed after BoNTA treatment, which led to further investigation on its potential analgesic 
efficacy. In 2010, BoNTA was approved for prophylaxis of chronic migraine; however, its 
mechanism of action is not fully known yet. Besides, BoNTA has become an option for many 
painful disorders in off-label studies. Elucidating its underlying mechanisms would enhance the 
possibility of further understanding its action and potentially its approval for other painful 
conditions. Moreover, BoNTA can be used as a pharmacological tool to study responsiveness of 
both neuronal and non-neuronal cells to different stimuli and substance release. Therefore, the 
purpose of this Ph.D. was to investigate potential BoNTA analgesic and antinociceptive 
mechanisms in 3 distinct studies applying different approaches. The first study investigated the 
time-course of pain relief from BoNTA in a human experimental pain model using psychophysical 
approaches and tissue imaging techniques. Healthy subjects were pre-treated with BoNTA in the 
temporalis muscle and saline as a control in the contralateral side and were followed in 4 sessions 
over 2 months. In each session, subjects received an artificially induced pain stimuli evoked by 
intramuscular injection of glutamate. BoNTA was able to exert its effect as early as 3 hours after its 
treatment, and this effect remained for 4 weeks, peaking at week 1. The second study involved a 
direct approach to measure glutamate, a potential substance released under painful condition, by 
means of a technique called microdialysis. Healthy volunteers received a subcutaneous injection of 
BoNTA in one forearm and saline in the other, and a week later, they were challenged by 
application of an experimental pain model of topical capsaicin combined with mild heat. This study 
revealed that BoNTA was able to reduce glutamate release in response to capsaicin pain model. 
Besides, BoNTA decreased pain and blood perfusion in the treated area when compared to the 
control side. Most studies have been focused on neuronal effect of BoNTA. Since the role of non-
neuronal cells in pain is being revealed gradually, the third study was designed as a basic back-
translational study on cells, to investigate effects of BoNTA on satellite glial cells (SGCs) of the 
peripheral nervous system from the trigeminal ganglia (TG) of rats. Isolated cells were cultivated 
for 7 days and were challenged by ionomycin to release glutamate after 24h of pre-incubation with 
BoNTA. In addition, in vitro and in vivo staining techniques were used to detect the presence of 
SNAP-25 and 23, the docking proteins that BoNTA cleaves to exert its effect and possibly inhibit 
the vesicular release of several substances that play a role in pain. This study revealed that SNAP-
25 and 23 are present in isolated cells as well as in sections of the TG. BoNTA, at a concentration 
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of 100pM, could block ionomycin-evoked glutamate release that is most likely by cleaving SNAPs. 
This study not only showed vesicular release of glutamate from SGCs, but also confirmed that 
BoNTA can exert inhibitory effects on non-neuronal cells of the peripheral nervous system. Results 
from these three studies advanced our understanding of the potential analgesic/antinociceptive 
mechanisms of BoNTA that eventually can yield beneficial evidence for further and extended 
application of this agent in several painful conditions.  
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1. Dansk sammenfatning  
Antinociceptive og analgetiske effekter af Botulinum neurotoksin type A: forklaring af de 
underliggende mekanismer 
På trods af fremskridt inden for smerteforskningen oplever mange patienter, at de ikke får optimal 
smertelindring eller får betydelige bivirkninger fra den medicin, der anvendes til behandling af 
deres lidelse. Botulinum neurotoksin type A (BoNTA) er et stof, som i flere år har været anvendt 
som muskelafslappende middel på patienter, der lider af neuromuskulære sygdomme samt 
muskelspændinger. Hos disse patienter ses smertelindring efter behandling med BoNTA. Dette har 
ført til yderligere studier i stoffets analgetiske virkning. I 2010 blev BoNTA godkendt til brug for 
kronisk migræne; dog kendes mekanismen bag virkningen ikke fuldt ud. BoNTA anvendes 
derudover som mulig behandling på smertefulde lidelser i off-label studier. Hvis de underliggende 
mekanismer blev belyst, ville det give en yderligere forståelse af stoffets virkning og dermed 
potentielt godkendelse til behandling af andre smertefulde lidelser. BoNTA kan anvendes som et 
farmakologisk værktøj til at undersøge følsomheden i både neuronale og ikke-neuronale celler i 
forhold til forskellige stimuli og frigivelse af stoffer. Formålet med denne ph.d.-afhandling var derfor 
at undersøge BoNTAs analgesiske og antinociceptive mekanismer i tre særskilte studier med 
forskellige fremgangsmåder. Det første studie undersøgte tidsforløbet for virkningen af BoNTA i en 
human eksperimentel model, der anvendte psykofysiske tilgange og vævsbilledteknikker. Raske 
forsøgspersoner blev forbehandlet med BoNTA i m. temporalis samt saltvandsopløsning som 
kontrol i den kontralaterale side, og forsøgspersonerne blev herefter fulgt i fire forsøgssessioner 
over to måneder. I hver session påførtes kunstige smertestimuli vha. intramuskulær injektion af 
glutamat. BoNTA kunne vise sin virkning så tidligt som tre timer efter smertestimulationen, og 
denne virkning fortsatte i fire uger, med maksimal virkning i den første uge. Det andet studie 
bestod af en fremgangsmåde til at måle glutamat; et stof, som frigives under smerte, ved hjælp af 
den såkaldte mikrodialyse-teknik. Raske forsøgspersoner fik en subkutan injektion med BoNTA i 
underarmen og saltvandsopløsning i den anden underarm. Efter en uge påførtes en smertemodel 
med topisk capsaicin i kombination med let varme. Studiet afslørede, at BoNTA kunne reducere 
glutamatfrigivelsen som reaktion på capsaicin-modellen. Derforuden formindskede BoNTA smerten 
og blodgennemstrømningen i det behandlede område sammenlignet med kontrolområdet. De 
fleste tidligere studier har fokuseret på den neuronale effekt af BoNTA. Da ikke-neuronale cellers 
rolle i smerte gradvist afdækkes, var det tredje studie designet som et bagudrettet translationelt 
basisstudie i celler til undersøgelse af BoNTAs virkning på satellit-gliaceller (SGC) i det perifere 
nervesystem fra den trigeminale ganglion (TG) hos rotter. Isolerede celler blev dyrket i 7 dage og 
blev påvirket ved hjælp af ionomycin til at frigive glutamat efter 24 timers præinkubation med 
BoNTA.  
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2. Introduction 
Pain is a debilitating condition that affects millions of people worldwide every year and 
chronic pain still remains as one of the major under-estimated and under-treated disorders (1). In 
2006, a study estimated that 19% of Europeans suffered from moderate to severe pain and, 
among those, most did not visit a pain specialist, and 40% alleged their treatment was not 
adequate (2). In Denmark, a fairly recent study estimated that 16% of the general population 
suffered from chronic pain. As in most countries, in Denmark, chronic pain is also undertreated, 
and more than 80% of chronic pain patients had never seen a pain management specialist (3).  
Pain is also a burden for societies from an economical point of view, impairing the 
productivity at work due to sick leaves, low functioning, and demanding enormous amounts of 
financial aid from governments (4). In a recent report by Global Industry Analysts, it was estimated 
that the global pain management market will reach US$60 billion by 2015. Besides, pain also 
relentlessly distresses patients’ social and personal life, reducing the quality of life of individual 
sufferers and their families significantly. Patients’ response to one treatment is not always in a 
similar way and adding comorbidities to a great variability can start the long path to find the optimal 
management plan (2,4).  
It is estimated that currently analgesic medications provide 50% of pain relief for about 
30% of pain patients’ population (5). Undoubtedly, many patients still suffer from suboptimal 
treatments and side effects from current medications. Pain research, after many decades, still 
faces several obstacles. It is imperative the need of more research to pursue better treatment 
options, reliable and direct tools to assess pain, and determine if patients will positively respond to 
the current treatments. In order to achieve this, it is important to better understand pain pathways 
to target those efficiently. Another issue in this research field is the translational aspects, which are 
not always predictable and effective (6). This means that even drugs that are proved effective in 
pre-clinical phases may not always be effective when they move to human clinical trials.  Analgesic 
drug development is therefore very challenging and not always successful (5,7). 
BoNTA has been showing promising results for pain treatment and more research is 
needed to show the toxin efficacy in different pain conditions to elucidate its mechanism, optimal 
dosing, and safe application to further expand its approval for other painful conditions. One of the 
main advantages of this compound is its long-lasting effect (8) and, in the last years, researchers 
have shown that BoNTA might be a suitable treatment option for several pain patients with different 
painful conditions (9-11). However, besides chronic migraine, its use for all other pain conditions 
still remains off-label.  
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2.1.  Human experimental pain models 
Studying a potential analgesic compound or investigating underlying mechanism in pain 
patients is challenging. In addition to some ethical limitations, most certainly, it would yield a great 
variability in outcomes due to variable nature of pain in this targeted population; hence, making it 
unreliable to interpret or replicate the obtained data. Besides, since in many cases pain 
mechanisms are not easily understood, the complexity would be even larger in comparison with 
other medical fields (12,13).  Experimental pain trials can therefore offer potential possibilities to 
overcome some of these challenges (14). One of the main advantages of experimental pain 
models is that one can partly focus on a particular involved mechanism and better assess the 
outcomes excluding confounding factors. However, only particular pain induction and assessment 
methods can be used in human volunteers or patients due to ethical limitations or safety reasons. 
Even though, when an experimental pain model is validated and well-established, it can be used 
for screening of potential analgesic compounds in early phases of drug development in a reliable 
and reproducible manner (15,16).  
Experimental pain models can be used as a tool to help researchers to deeper investigate 
detailed aspects of a specific nociceptive input. Even though these models might not exactly mimic 
clinical situations, they still aid providing better insights for clinical studies and are broadly used to 
peripheral and central aspects of pain research. All available pain models share two common 
features: they utilize a standardized method to activate the nociceptive system, creating a painful 
stimulus and, once that is reached, a variety of measurements are used to assess the outcomes, 
that can be based on psychophysical, electrophysiological, or imaging techniques (17). These 
models can also be used to investigate hyperalgesia, that is an increased pain sensation caused 
by a normal noxious stimulus or allodynia, which is a painful experience caused by a stimulus that 
is usually not painful (14). These phenomena are often seen in chronic pain patients; thus 
experimental models that can mimic these aspects are highly relevant. 
Several human experimental pain models have been tested and established and are now 
available and broadly used to induce an artificial state of pain. Pain induction methods vary from 
induction by aid of thermal, electrical, mechanical to chemical stimuli isolated or combined. The 
ideal pain stimulation would be the one that evokes a distinctive pain, exciting only certain 
nociceptive fibers, with as minimal tissue damage as possible and with a relationship between the 
stimulus and pain intensity. Besides, it should have a reliable intra and inter-session reproducibility 
(13-15,18). 
In order to enhance the feasibility of an experimental model, it is imperative the need of a 
planned study design bearing in mind the available options for the pain model as well as for the 
measurement techniques. To better choose the optimal pain model, the researcher has to consider 
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the characteristics of a model and the purposes of an experiment, making sure the assessment 
techniques are relevant and available (14,15). For instance, in this Ph.D. project, two experimental 
models of pain were applied: injection of glutamate and topical capsaicin combined with heat 
stimulation. Both these models have been used safely in the humans with acceptable and reliable 
features required for studying pain pathways and analgesic drug mechanisms for this project.  
2.2.  Glutamate 
Glutamate is a well-known excitatory neurotransmitter with an important mediatory and 
modulatory role in nociception and sensitization and is thoroughly investigated in the central 
nervous system (19). However, many evidences show that glutamate is also an important 
component involved in peripheral nociception (20,21). In animals, elevated levels of interstitial 
glutamate were found in peripheral tissues after nerve stimulation, capsaicin, and formalin induced 
pain model (22,23). In humans, increased levels in peripheral glutamate release have been 
observed due to chronic and inflammatory conditions (24-27). There is evidence that non-neuronal 
cells can also release glutamate, like astrocytes (28) and Schwann cells (29), contributing to 
maintaining the pain state and possible central and peripheral sensitization, respectively. It has 
also been shown that activation of peripheral glutamate receptors contributes to nociception and 
peripheral sensitization (30-32) and that the number of glutamate receptors is increased in the 
periphery during inflammation (33). It is evident that glutamate and its receptors are involved in 
pain pathways and it is believed that the modulation of both glutamate and its receptors could be 
used as a potential option to treat persistent pain (both neuropathic and inflammatory pain) (22,34). 
Since glutamate is involved in pain modulation, it has been considered and used as a 
potential substance in experimental pain model. Glutamate injection has been used to evoke 
experimental pain in animals and humans (30,35-39). Injection of glutamate in the peripheral 
tissues activates peripheral glutamate receptors and has been used as a model to induce pain, 
sensitization, and neurogenic vasodilation. For example, glutamate injection in the masseter 
muscle or in the temporomandibular joint has been used as a TMD (temporomandibular disorder) 
pain model both in animals and humans (35,37,40).  
It has been broadly shown that the injection of glutamate into human muscles evokes pain 
and mechanical sensitization and that is mediated, at least in part, through activation of peripheral 
glutamate receptors (30,37,38,41,42). When ketamine, an NMDA receptor (N-methyl-D-aspartate 
receptor) antagonist was injected, it could block the glutamate induced pain and revealed that 
glutamate receptors are involved in the peripheral effect of glutamate to induce pain (43). 
Glutamate-induced neurogenic vasodilation was also found to be mediated in part by the 
vasodilatory neuropeptides calcitonin gene-related peptide (CGRP) and, to a lesser extent, by 
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substance P. In study I of this Ph.D. project, it was hypothesized that if glutamate release is 
contributing to peripheral pain and sensitization, blockade of its release would result in reduced 
pain and sensitivity in the peripheral tissues. Therefore, an injection of glutamate in the temporalis 
muscle was used as an experimental pain model in presence and absence of BoNTA, which is a 
compound that can block the release of neurotransmitters, such as glutamate via SNARE 
dependent mechanisms. 
2.3. Capsaicin 
Capsaicin is the active compound from chili pepper that gives the hot and pungent 
sensation. This extract is also largely used as a pain model that causes a burning pain and a 
distinct flare reaction. Capsaicin-evoked pain, sensitization, and vasomotor reactions may partially 
mimic the mechanism underlying both inflammatory and neuropathic pain. When injected or 
applied topically, it activates the transient receptor potential vanilloid 1 (TRPV1) located on C-fibers 
of peripheral nociceptive sensory neurons (44,45) and provokes release of some substances, e.g. 
glutamate and/or CGRP. While the capsaicin injection produces a faster and stronger pain 
response for a short period of time, the topical application takes a longer time to get a similar 
response, but provides a more stable plateau. The effect seen following the topical formulations of 
capsaicin is highly influenced by skin stratum cornea depth, the skin vascular network, and 
temperature. In comparison between the routes of administration of capsaicin, the injection 
remains more reliable than the topical application, since it is not easy to determine exactly the 
concentration of capsaicin that is being absorbed and metabolized by the body to reach the 
expected response (44).  
Interestingly, capsaicin is also used in a topical formulation to treat pain, including 
neuropathic pain (46), painful HIV neuropathy (47), and postherpetic neuralgia (48). The first usage 
is usually done after local anesthesia, because patients will experience the burning pain and 
sensitization caused by capsaicin. In the second treatment, they face a reduced sensitivity period 
and after repeated topical capsaicin application, they enter a desensitization phase. It is believed 
that the mechanism of action for this desensitization is through the depletion of substance P from 
the sensory nerve endings after repeated capsaicin application (49). Low concentration creams 
and lotions have been used for a few decades; however, recently, a high concentration capsaicin 
patch 8% (Qutenza®) was approved for pain treatment of painful peripheral neuropathies. The 
patch application is usually for 30 minutes and pain relief is due to last for 12 weeks (50,51). The 
phenomenon of first application causing burning pain with capsaicin patch was therefore used as 
the basis for the experimental pain model in the study II described in this Ph.D. thesis. Hence, it 
was combined with mild heat to increase the response. The heat/capsaicin sensitization model was 
established in 1999 by Petersen KL and colleagues (52), and it is based on the synergistic effect 
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from capsaicin and the mild stimuli from heat, which together will be greater than both of them 
applied separately. This model was proved to be more stable than capsaicin alone or heat alone. 
Since there was no record of using the patch with mild heat in literature, a pilot study was done 
before study II, where the efficacy of the model was approved. For the described study, it was 
hypothesized that if glutamate is released following the application of capsaicin plus mild heat, 
BoNTA can potentially block it. Therefore, release of glutamate in this model was investigated in 
presence and absence of BoNTA. 
4.4. BoNTA 
Botulinum neurotoxin type A is one of the seven serotypes of the neurotoxin produced by 
the gram-positive anaerobic bacterium Clostridium botulinum (53). For the last decades, BoNTA 
has been used in the treatment of disorders characterized by pathologically increased muscle tone, 
such as hemifacial spasm, dystonia, spasticity, strabismus, and cerebral palsy (54-57). In addition, 
it was also revealed that when the toxin was injected in the post-ganglionic cholinergic fibers it 
induced chemical denervation in the area, becoming useful for the treatment of hyperhidrosis and 
reduction of salivary secretions and drooling (58-60). Early observations in dystonia also 
demonstrated an analgesic effect of BoNTA (55,61), which led to further investigation on its 
efficacy for painful conditions. Currently, chronic migraine is the only pain condition that BoNTA 
treatment is regulated and approved for (62-64). However, BoNTA has proved beneficial and has 
been used off-labeled as an alternative treatment for several other painful conditions, like 
neuropathic pain (9,65,66), low back pain (10), myofascial pain syndrome (67,68), fibromyalgia 
(11) among others. 
4.4.1. Mechanism of action 
BoNTA’s mechanism of action in muscle relaxation is well established, and it has proved 
useful for conditions with muscle hyperactivity. When injected intramuscularly, BoNTA inhibits the 
exocytotic release of acetylcholine at the neuromuscular junction leading to muscle relaxation. 
Following the injection, the toxin molecule is transported to the cytosol of the pre-synaptic neuron 
and there, the light chain selectively cleaves the SNAP-25, one of the proteins of the SNARE 
complex. This complex is responsible for the docking of vesicles containing acetylcholine and 
several other substances and neurotransmitters, e.g. glutamate and CGRP. When SNAP-25 is 
cleaved, the whole complex is not functional and these storing vesicles cannot attach and fuse to 
the membrane to release the acetylcholine that would further promote the muscle contraction (69-
72). Figure 1 shows a detailed schematic of the mechanism of action of BoNTA in the synaptic 
cleft. 
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Figure 1: Left panel shows the normal acetylcholine release from the synaptic vesicles. In order to 
be released, the vesicles get attached to the pre-synaptic membrane through the SNARE proteins, 
fuse to the membrane, release acetylcholine and the muscle contracts normally. When BoNTA is 
present (right panel), the botulinum toxin is endocytosed to the motor neuron; the light chain of the 
toxin is translocated to the cytosol and cleaves the SNAP-25, one of the membrane proteins that 
form the SNARE complex. As a result, the vesicle containing acetylcholine will not fuse to the 
membrane, will not release acetylcholine, and the muscle will not contract. This figure shows 
vesicles containing acetylcholine, but it is believed that the same occurs for other neurotransmitters 
(e.g. glutamate and CGRP) that are also stored in vesicles and are released through the same 
mechanism. Reproduced with permission from (73), Copyright Massachusetts Medical Society. 
 
For a long time, it was widely assumed that when injected peripherally, BoNTA wouldn’t 
leave the synaptic terminal and its effects would be confined to the injection site. However, 
evidences are accumulating for potential central effects of BoNTA when it is peripherally 
administered. Some animal studies provide direct and indirect evidence that when injected 
peripherally, BoNTA is retrogradely transported through axonal migration and neuronal 
transcytosis from the injection site to the centrally located centers of the nervous system (74-77). 
Further investigation is needed in order to better elucidate the exact mechanism for this transport 
and whether it is the toxin molecule or the already cleaved SNAP-25 that migrates and exerts its 
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action. Awareness is being brought to this issue since it can change the clinical applications of 
BoNTA. Anyhow, it is important to consider that either way, peripheral treatment with BoNTA will 
have a combination of peripheral and central effects, by either reaching central part by retrograde 
transport or by indirectly influencing central sensitization. It is proposed that BoNTA blocks the 
release of nociceptive substances and inhibits peripheral sensitization, which would then result in 
an indirect decrease of the central sensitization (8,78). This might be, at least in part, one of the 
underlying mechanisms for analgesic effect of BoNTA in chronic migraine. Most experimental 
knowledge regarding the antinociceptive mechanisms of BoNTA is based on in vivo animal models 
(79-81) and in vitro culture systems (78,82-86). A detailed schematic of BoNTA action in the 
peripheral and nervous system is exemplified in figure 2. 
 
Figure 2: Peripheral and central effects of BoNTA. The upper part of the figure (A) shows the 
sensitization of the peripheral and central system under normal conditions. When the tissue 
undergoes an injury or other stimuli, as a response, neuropeptides and inflammatory mediators are 
released resulting in the peripheral sensitization, which will result in an increased amount of signal 
through the spinal cord or trigeminal nucleus, inducing the sensitization at the central nervous 
system (CNS). The lower panel (B) shows how BoNTA influences the peripheral and central 
sensitized states. When present, BoNTA directly inhibits the peripheral sensitization by blocking 
the release of neurotransmitters, which, in turn, will indirectly impact and inhibit the central 
sensitization. Reproduced from (8) with permission from Elsevier. 
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4.4.2. Analgesic effect 
It is believed that BoNTA suppresses the release of substances involved in pain and 
vasodilation, e.g. glutamate and CGRP (8). The analgesic effect of BoNTA is supported through 
many experimental pain models in animals and humans that present positive results for BoNTA’s 
antinociceptive or analgesic efficacy (8,9,78,80,87,88). However, efforts are still being made to 
further investigate BoNTA’s effects and elucidate unknown information, e.g. the optimal dose and 
interval, best route of administration, how far the toxin molecule spreads and its consequence, 
among many unanswered questions. If a modulatory role is confirmed in pain pathways both in the 
periphery and possibly at the central levels, BoNTA can actually be an option for many other 
painful conditions besides chronic migraine, blocking pain transmission and its maintenance. 
The beneficial effect of BoNTA in migraine was confirmed through multiple clinical trials 
and OnabotulinumtoxinA has been recently approved for chronic migraine. The recommended 
dosing from the manufacturer (Allergan®) is 155 Units divided into 31 injection sites along 7 
different muscles, including the craniocervical muscles such as the temporalis, frontalis and 
trapezius muscle. Even though, the exact mechanism of BoNTA in migraine still remains unknown. 
Recently, a study indicated that injection of BoNTA into the temporalis muscle, a site for 
administration of BoNTA for migraine prevention, decreases the mechanical sensitivity of 
temporalis muscle nerve fibers in female rats (39). It is also believed that the sensitization in the 
trigeminovascular system may play an important role in migraine pathophysiology (89,90). BoNTA 
may eliminate local, painful pericranial muscles (migraine triggers) to avoid further attacks. 
However, pain relief occurs prior to muscular relaxation or in areas with no muscle tension (91). 
Therefore, muscle tension and relaxation by BoNTA cannot be the sole responsible cause, and 
prolonged muscle sensitization might be responsible for indirect cause or maintenance of central 
sensitization.  
Even though the efficacy of BoNTA for pain treatment is prevailing, there is still 
divergence between the analgesic efficacy of BoNTA (92-94) and the time course of effect when 
comparing clinical and experimental studies. While in the experimental settings the differences are 
seen from as early as 3 hours after the BoNTA treatments (39) and peaks 1 week after (42), at the 
clinic, physicians start to notice the analgesic effects later on, and the greatest effect is believed to 
peak around 1 month after the treatment (62,63).  
One of the main advantages of BoNTA can be its long-lasting effect when compared with 
other analgesics that are limited to frequent intake. This is especially valuable when treating elderly 
patients or those on polypharmacy where other comorbidities are present (e.g. difficulty in 
swallowing several pills). Even though injection is the only available route of administration of 
BoNTA at the present time, which may limit its use due to patients’ compliance for injections in 
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general, that can bring the advantage of reducing the oral intake medication and decreasing the 
risk of over or under dosage. Besides, the treatment is also considered to have a reasonable 
safety profile (9,95).  
For a long time, it was believed that only neurons were involved in pain pathways, 
however, in the past years, non-neuronal glial cells became a novel and promising target for pain 
research and treatment (96,97). Previously, glial cells were acquainted for mainly support of the 
neurons in the central and peripheral nervous system. Now, however, they are being linked as an 
important component to pain initiation and its maintenance. By targeting these non-neuronal cells, 
alterations can be seen at structural levels and by loss of release of pain mediators and pro-
inflammatory substances (96,98). Nevertheless, researchers have mainly focused on astrocytes 
and microglia, the main residents’ glial cells of the central nervous system, in connection to pain. 
However, peripheral glia, e.g. satellite glial cells (SGCs), is also known to contribute to pain 
transmission. To explore potential role of SGCs and their activity modulation by BoNTA, the study 
III of this Ph.D. project was designed. It was hypothesized that SGCs can release glutamate 
through vesicular mechanisms and that this phenomenon can be blocked by BoNTA via interacting 
on SNARE proteins (SNAP-25 and 23) presented in SGCs.       
Taken together, although some aspects of antinociceptive and analgesic actions of 
BoNTA are known, there are still several details on underlying mechanistic points to be explained. 
Those aspects include (but are not limited to) its direct and indirect effects both at neuronal and 
non-neuronal levels and further elucidation on reasons for mismatch between clinical and 
experimental time-course of effects. Therefore in this Ph.D. project, an attempt was made to 
contribute to addressing some of these points with a focus on inhibitory role of BoNTA in 
association with glutamate in pain mechanisms. 
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5. The Ph.D. Project 
5.1. Aims 
The main focus of this Ph.D. was to further investigate the analgesic/antinociceptive effect 
of BoNTA through direct and indirect methodological techniques. To achieve this goal, three 
different and novel studies were proposed to elucidate potential analgesic mechanisms of BoNTA. 
The first study was a psycho-physic methodological study that investigated the time-course 
analgesic effect of BoNTA on a glutamate-induced experimental pain model in humans. A dermal 
microdialysis technique, in study II, was used as a tool to directly investigate whether BoNTA could 
alter glutamate release when it was evoked by an experimental pain model of topical capsaicin 
combined with mild heat. In these two studies, pain, vasomotor responses and, sex-related 
differences were also investigated. Study III explored the potential inhibitory effect of BoNTA on 
vesicular release of glutamate from non-neuronal SGCs isolated from the rat trigeminal ganglia 
(TG). Imaging techniques (IHC and ICC) were also used in this study to investigate the presence of 
SNAP-25 and 23, the docking proteins that are cleaved by BoNTA.  
 
Figure 3: Outline of the Ph.D. project. The analgesic effect of BoNTA was the common ground for 
the 3 studies.  
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5.2. Study hypothesis 
It was hypothesized, that BoNTA would decrease pain and vasomotor reactions induced 
by glutamate and capsaicin combined with mild heat, in study I and II, respectively. In these two 
human experimental studies, an indirect approach was taken to assess the time course and sex-
based differences of potential analgesic effects of BoNTA. Besides, in study II, a direct 
measurement approach was also applied (microdialysis), and it was proposed that BoNTA would 
reduce or block the glutamate release in correlation with pain or vasomotor reductions. In study III, 
a cell-based platform was used in which it was suggested that SGCs would have expressed 
SNAPs (SNAP-25 and SNAP-23). This is the membrane protein to be cleaved by BoNTA and that 
would reduce the release of glutamate from the cultured trigeminal SGCs, when they are activated 
by ionomycin, a pharmacological tool to evoke calcium-dependent glutamate release.  
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6. Description of the studies 
6.1. Study I 
Time course analysis of the effects of Botulinum neurotoxin type A on pain and vasomotor 
responses evoked by glutamate injection into human temporalis muscles. 
6.1.1. Aims and hypothesis  
The aim of this study was to examine the time-course of events in the human 
experimental pain model induced by injection of glutamate into temporalis muscle of healthy men 
and women in presence and absence of BoNTA. Glutamate-evoked pain model in temporalis 
muscle of humans was used to mimick some aspects of trigeminal pain and sensitization seen in 
craniofacial pain conditions, e.g. headaches. This was a translational study from a similar animal 
experiment in order to investigate similarities and differences in time course of events seen in this 
model between rat and human. 
We hypothesized that the glutamate injection would elicit pain, induce a mechanical 
sensitization, and increase the temperature and blood flow when compared to the saline treated 
side. We also proposed that the pre-treatment with BoNTA would decrease the pain, increase the 
mechanical thresholds, and would reduce the glutamate-induced vasomotor reactions in the 
human temporalis muscle. These expected results would be a consequence of suppression 
release of neurotransmitters from peripheral nociceptive nerve endings in the treated muscle by 
BoNTA and that this response might be different in men and women.  
6.1.2. Main findings 
The intramuscular injection of glutamate into the temporalis muscle proved to be effective 
in eliciting a short-lasting trigeminal human pain model, besides increasing the skin temperature 
and blood flow in the treated area. However, the glutamate injection did not cause a detectable 
muscle mechanical sensitization, limiting the possibility to test the reversibility by BoNTA. But it 
was found that the BoNTA pre-treatment of the temporalis muscle decreased the glutamate-
induced pain and vasomotor responses with no side effects from as early as 3 hours after its 
treatment and its peak was seen at day 7. Glutamate itself induced more pain in women, and when 
pre-treatment with BoNTA was made, women had a higher skin temperature while, men presented 
a higher skin blood flow (for details of this study please refer to Paper I). 
6.1.3. Conclusion  
This study revealed that the analgesia due to intramuscular injection of BoNTA may occur 
within a few hours (3 hours), even though clinical data show that this onset is present only later on. 
The time course of the events in this study was very well matched with our previous animal study 
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and suggests that most likely under acute experimental pain conditions both in humans and 
animals, BoNTA acts rapidly within few hours. It is therefore suggested that the rapid onset, at 
least partially, might be due to direct action of BoNTA in blocking vesicular release of neuroactive 
substances on peripheral nociceptors, and altered sensory processing in pain patients might need 
longer duration to be modulated by the toxin or the central effect of the toxin in chronic pain 
conditions develop over time, directly or indirectly. With current technology and methods applied in 
human studies, it is not easy to speculate what the reasons are for a delayed effect of the toxin 
analgesic effects in pain patients in comparison with animal and human experimental findings. We 
also found sex-related differences, which were limited to vasomotor responses. There is no report 
available on sex-based responsiveness in patient population. In chronic migraine, due to the 
disorder nature occurring three times more in females than males, it might not be easy to interpret 
if there is any sex-related response to the toxin, so it needs further investigation. 
6.2. Study II 
Blockade of glutamate release by Botulinum neurotoxin type A in humans: a dermal microdialysis 
study. 
6.2.1. Aims and hypothesis  
The aim of this study was to investigate the mechanism of BoNTA on the pattern and level 
of glutamate release induced by a topical capsaicin patch (8%) with mild heat in the human skin. 
The study further investigated the effect of BoNTA on pain response in capsaicin-sensitized skin, 
including the vasomotor response. This study was the first in humans to use the direct approach 
for following the blockade of glutamate release by BoNTA in human skin. Previously, a similar 
result was shown with the formalin model in the hind paw of rats. We found the dermal 
microdialysis as the best approach to investigate release responses and modulations in a 
minimally invasive way, and still translatable to what has been already shown in animals.  
We hypothesized that a subcutaneous injection of BoNTA would alter the pattern of 
release of glutamate, which is potentially involved in the transmission of pain following a challenge 
test using capsaicin and mild heat. These changes were proposed to be detectable by dermal 
microdialysis in the human skin. It was also proposed that BoNTA would decrease pain sensation 
and vasomotor responses in correlation with glutamate release blockade. 
6.2.2. Main findings 
The BoNTA pre-treated side showed positive results in decreasing the pain intensity and 
suppressing the skin blood flow after the capsaicin plus mild heat pain model. BoNTA also 
significantly lowered the release of glutamate in the treated area when compared to the saline side. 
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These responses were sex-independent. This was the first evidence in humans that BoNTA 
attenuated glutamate release in the human skin and supports the previous findings in animals. We 
found a correlation between the increased glutamate levels and skin blood flow, but no correlation 
was found between glutamate levels and pain or skin temperature. Hence, this study provided the 
first evidence that blockade of glutamate release may contribute, partly, to the peripheral analgesic 
effects of BoNTA (for details of this study please refer to Paper II). 
6.2.3. Conclusion  
This study demonstrated that BoNTA attenuated the release of glutamate in human skin 
when it was provoked by capsaicin plus mild heat. Although BoNTA inhibited the provoked pain, 
only an association between BoNTA reduction in glutamate release and provoked blood flow 
response was found, not pain per se. There might be some pathways involved in pain response 
distinct from vasomotor responses to BoNTA in association with glutamate, which calls for further 
investigation. 
6.3. Study III 
Botulinum neurotoxin type A modulates vesicular release of glutamate from trigeminal satellite glial 
cells. 
6.3.1. Aims and hypothesis  
The present study aimed at finding whether SNAP-25 and SNAP-23 are expressed in 
cultured trigeminal SGCs, if those cells would release glutamate in a time- and calcium-dependent 
manner following stimulation by ionomycin, and if BoNTA would block or decrease the vesicular 
release of glutamate from these cells. The purpose of study III was not only to study possible 
role(s) of peripheral non-neuronal cells (SGCs) in trigeminal sensory transmission, but also to 
advance our understanding about mechanism(s) of analgesic action of BoNTA at the level of 
sensory ganglia. 
It was hypothesized that SNAP-23 and SNAP-25 would be present in the isolated cells 
and in the trigeminal tissue section. This was based on the fact that SNAP 25 is well known to be 
present on neurons, but the presence of SNAPs on non-neuronal glial cells is not well studied and 
there was limited information on central glia for the expression of these membrane proteins.  The 
intention was to see if SGCs in the peripheral sensory ganglia can modulate pain via vesicular 
release of glutamate. Therefore, it was proposed that ionomycin would be able to induce calcium-
dependent glutamate release from these cells and that BoNTA would be able to reduce or block 
the vesicular release of glutamate from the cells based on the action on SNARE proteins.  
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6.3.2. Main findings 
It was demonstrated that the cell membrane docking proteins SNAP-25 and SNAP-23 
were present in the primary cultures of trigeminal SGCs and in the TG tissue. These are the 
proteins that BoNTA cleaves to exert its effect. Therefore, it is possible to study the antinociceptive 
effect of BoNTA at the level of sensory ganglia. Moreover, it was verified that cultured SGCs, when 
stimulated with ionomycin, can release glutamate, which is most likely based on a vesicular 
release. Besides, BoNTA was able to inhibit this vesicular release of glutamate, possibly by 
blocking the docking proteins presented in those cells. Up to date, this is the first evidence showing 
that trigeminal SGCs contain SNAPs and, most likely through cleavage by BoNTA, glutamate 
release can be inhibited and influence the pain transmission at this level (for details of this study 
please refer to Paper III). 
6.3.3. Conclusion  
The results from study III shed light on possible role of SGCs in trigeminal pain 
transmission and the antinociceptive action of BoNTA at the level of trigeminal ganglion, with an 
emphasis on the role of non-neuronal cells. Further investigation is required on how BoNTA can 
reach the sensory ganglia after peripheral injection and whether it is the toxin itself or the cleaved 
format and under which conditions it can exert its potential effects. The safety aspect of such 
modulation needs to be further investigated.  
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7. General methodological approaches 
The local ethics committee (Region of North Jutland, Denmark) approved the 2 human studies 
(studies I and II). The same investigator (author) performed the experimental procedures following 
the Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki. Before both 
experiments, all subjects, who were recruited through on-campus advertisements at Aalborg 
University, Denmark, were screened by the responsible physician to assess the fulfillment of 
studies criteria. For the cell study (study III), all procedures were conducted according to ethical 
guidelines defined by the Danish Animal Experiments Inspectorate in accordance with the 
guidelines set by International Association for the Study of Pain (IASP) for use of laboratory 
animals in medical research. The following section provides details on the methodological 
approaches used in the course of this Ph.D. project with a main focus on the details that are not 
provided in the papers (I, II, III). In addition, methodological considerations and limitations are 
presented further on item 9. 
7.1. Study I 
This study included healthy young volunteers from both sexes to provide a most homogenous 
group with a balance in number, age and sex of the participants (thirty subjects, 15 men (mean age 
±SEM: 23.6±0.51 years) and 15 (23.3±0.62 years) women). Besides the session that the pain 
model was validated (glutamate-induced experimental pain model), the volunteers participated in 5 
experimental sessions after the screening, including a treatment session (BoNTA and saline) and 
four follow-up sessions (3 hours and 7, 30 and 60 days following BoNTA). This design allowed the 
investigation of time course of events (glutamate-evoked pain and vasomotor responses) in 
presence and absence of BoNTA.   
7.1.1. Glutamate-evoked pain model 
Glutamate is one of the most important and abundant excitatory transmitter in the nervous system 
and its injection in the different tissues, e.g. skin and muscle, has been used as a pain model in 
animal and human studies (30,38). As explained in item 4.1, there are several available options of 
experimental pain models. The first study in this Ph.D. was a translational experiment from a 
previous animal study from our group where glutamate injection into the rat temporalis muscle was 
also used as an experimental pain model (39). Therefore, an injection of glutamate into the 
temporalis muscle was used as an evoked pain model in humans, which carries a safe profile; it is 
short lasting and is also a well-tolerated substance to induce an artificial pain state. The first part of 
the study was designed as a placebo controlled study (glutamate versus saline). This way 
glutamate and isotonic saline were injected randomly (left versus right) into the temporalis muscle. 
This study was also designed as a blind study, in which subjects were unaware of the content of 
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the syringes. The second part consisted of the investigation of the time-course of BoNTA as an 
analgesic compound followed by glutamate injection on both sides of the temporalis muscle.   
7.1.2. BoNTA 
BoNTA was the main investigational compound and was used in all of the 3 studies. For the first 
study, each vial of BoNTA (BOTOX®, Allergan, Inc., Irvin, CA; 200 U/vial) was reconstituted with 
preservative-free 0.9% Sodium Chloride Injection. Each subject received one single injection of 
BoNTA into the anterior temporalis muscle (5 U/0.1 mL). The same volume of sterile physiological 
saline (0.1 mL, 0.9%) was injected into the contralateral anterior temporalis muscle to serve as a 
vehicle control injection. BoNTA injections were given at the Neurology Department, Aalborg 
Hospital, where all safety precautions were implemented. The injection sides were randomized and 
both the experimenter and subjects were blinded to the content of the injections. 
Electromyographic (EMG)-guided injections with disposable needle electrodes were used in order 
to ensure intramuscular injection. In order to ensure that the BoNTA pre-treated site was identified 
for the subsequent sessions, a transparent sheet was used and mapped with ink. 
7.1.3. Assessment of pain  
Pain is described as an unpleasant sensory and emotional experience that is associated with 
actual or potential tissue damage or described in such terms (99). It can also be influenced by 
personal and emotional feelings that can override the actual experience. Since pain is a subjective 
measurement, a self-rating from patients’ remains as the most used and direct approaches to try 
and quantify pain in experimental settings and also in daily clinical practice. VAS (visual analogue 
scale) is a common tool used in experimental and clinical settings to help researchers and 
clinicians to follow induced or spontaneous ongoing pain (100). These scales can be presented as 
simple as a numerical scale or as an electronic version, but both are rated from 0 to 10 or 0 to 100, 
where the 0 usually means “no pain” and the other extremity means “the most pain imaginable”. 
Pain can be rated continuously or at specific time points. From the subjects’ ratings it is possible to 
extract different outcomes that can be used and analyzed separately: peak pain (the highest VAS 
score), duration of pain and AUC [AUC VAS (cm × sec)]. For the present study, glutamate-evoked 
pain was rated continuously by the subjects on an electronic scale (from 0 to 10) for 10 minutes 
after the injections and peak pain intensity and the area under VAS curve were extracted and used 
for analysis. Besides VAS, another simple method to graphically represent pain is drawing the 
perceived pain. This experiment used a face chart drawing that was given to each subject after 
resolution of the glutamate-evoked pain. After being shown where they received the glutamate 
injection, they were asked to draw the area of perceived pain on the chart. VistaMetrix (SkillCrest, 
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LLC, version 1.3) was used for quantitative data extraction from graphics and used to calculate the 
area in arbitrary units.  
7.1.4. Pressure pain threshold 
PPT is one of the biomarkers that can be used for pain assessment, diagnostic purposes, and also 
evaluation of response to analgesic treatments. Pressure algometry is a technique that applies an 
increasingly constant pressure (in kPa/s), and it is used to assess the mechanical sensitivity of 
muscle and deep tissues. Both threshold and tolerance can be measured for different purposes. In 
study I, PPT was used to measure the mechanical sensitivity of the temporalis muscle after the 
glutamate injection and compared to the baseline. Subjects were instructed that the PPT is ‘the 
point at which the pressure sensation just becomes painful’. The pressure was delivered at a 
constant rate while the algometer tip was applied perpendicularly at the target tissue. 
7.1.5. Thermography 
Thermo imaging is a refined and well-known technique for non-invasive monitoring of tissue 
temperature surface (101). This is a direct measurement that enables the investigator to follow 
temperature changes in the skin, from the superficial muscle or tissues below that will have the 
temperature changes reflected in the skin. These changes will most likely arise from the dilatation 
or constriction of the arterioles that lay bellow the skin and control the skin temperature (102). 
These measurements were performed by means of a non-contact infrared thermographic camera 
(FLIR Systems, Inc., -Stockholm, Sweden) that captures infrared wavelength (700 nm – 1 mm).  
7.1.6. Blood flow (LDI) 
Laser Doppler imaging (LDI) is a sophisticated and well stablished scanning technique for non-
invasive monitoring of microvascular perfusion often referred to as microvascular blood flow or red 
blood cell flux (101,103). This technique enables a real time measurement of the moving red blood 
cells inside the vessels, like arterioles and veins, in the skin surface. LDI works through a laser 
beam that scans the skin without contact through a moving mirror. While the low power laser 
source is directed to the targeted area through this moving mirror and scans the surface of the 
skin, its frequency is then shifted when it encounters moving elements, like the red blood cells. 
This frequency, changed or not, is detected by a photodetector and collected by the sourced 
computer that generates a color coded image that represents the blood flow from the scanned area 
(103).  
7.2. Study II 
Healthy volunteers from both sexes were recruited for this study in order to provide a most 
homogenous group with a balance in number, age and sex, and they consisted of 6 men (mean 
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age ± SEM: 25.0±1.5 years) and 6 women (25.7±0.72 years). Potential subjects were asked to 
attend a screening session where they were challenged with the intended pain model. This was 
performed, because previous pilot studies showed that some participants did not present any 
response after capsaicin stimulation. For the present study, only the participants that developed a 
visible flare and rated the capsaicin-induced pain intensity above 5 (VAS 0 to 10) were included. In 
order to have a more homogeneous group regarding body composition, weights and heights were 
checked and only participants with body mass index (BMI) between 19 kg/m2 and 35 kg/m2 were 
included. After that, the experimental sessions followed with the first as BoNTA and saline (control) 
treatment injection in each forearm in a random blinded fashion. One week later, subjects were 
challenged by topical capsaicin patch (8%) plus mild heat, while having a microdialysis membrane 
in the pre-treated area. 
7.2.1. BoNTA 
Similarly to the study I, each vial of BoNTA (BOTOX®, Allergan, Inc., Irvin, CA; 100 U/vial) was 
reconstituted with preservative-free 0.9% Sodium Chloride Injection. Each participant received a 
single injection of BOTOX® (10 U/0.2 mL) with disposable needle intradermally in the volar part of 
the forearm, 5 cm distant from the cubital fossa. The equal volume of sterile physiological saline 
(0.2 mL, 0.9%) was injected as control in the contralateral forearm. The sites of injections were 
mapped on a transparent sheet for further location tracking for the microdialysis membrane 
insertion.  
7.2.2. Capsaicin + mild heat-induced pain model 
Capsaicin is a well-known model causing a short burning artificial pain. The capsaicin-heat model 
is also well-established and presents some useful aspects, like mimicking both neuropathic and 
inflammatory aspects. This model was selected because of its stability, besides the combination of 
topical application and lack tissue injury. Before the application of the capsaicin patch, the area 
was pre-sensitized with a heat stimulation of 45°C for 5 minutes. The patch was cut as a rectangle 
that covered the pre-treated BoNTA site and was applied for 1 hour to the just sensitized skin, right 
in the middle of the 2 probes to ensure the stimulation was in the best place to capture the 
changes. In order to increase the response, a mild heat (40°C) was used, avoiding the 
microdialysis membrane to ensure it would not damage it.  
7.2.3. Assessment of pain 
Pain measurement technique by VAS was explained in item 6.1.3. In study II, pain scores were 
recorded right after the membrane insertion, following the heat sensitization period and every 15 
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minutes from the capsaicin patch application. The peak pain intensity scores were manually 
recorded and used for statistical analysis. 
7.2.4. Thermography 
The thermography technique is explained in item 6.1.5. For study II, measurements were 
performed before the membrane insertion (baseline) and every hour, for 3 hours after the insertion. 
While the baseline measurement was performed with the intact and uncovered skin, the 
subsequent measurements were taken after probe insertion or placement of patch on the 
canulated area.  
7.2.5. Blood flow (FLPI) 
Similarly to study I, skin blood flow was also measured; however, a laser speckle contrast imager 
(Moor Instruments, Devon, UK), which consists of another device to monitor vasomotor changes in 
the treated area, was used. This full-field laser perfusion imager device (FLPI) uses a full field laser 
technique and provides real-time and high-resolution images of blood flow. The technique is non-
invasive and is based on a random speckle pattern that is generated when tissue is illuminated by 
the laser light to capture the blood cells’ movements.  
7.2.6. Microdialysis 
Microdialysis is an in vivo technique that can be used to continuously monitor the release of 
substances and responses to drugs and procedures in virtually any tissue of the body. In study II, 
this approach was used in the dermis of the forearm to measure the pattern of glutamate release. 
Before the membrane insertion, an ice pack was used in the intention area for 5 minutes to cause 
a numbness of the skin and decrease the amount of pain. Two linear probes (10 mm length, 100 
kD cut-off) were inserted in each of the subjects’ arms with the BoNTA pre-treatment injection in 
the middle. Figure 4 shows in details the schematic and disposition of probe placement and 
insertion along with the pain model application site. After the probes were in the correct place, they 
were attached to an adjustable pump that was set to 3 µL/min, as a perfusion rate. Samples were 
collected overtime from both arms. The glutamate recovery of the experimental system was 
evaluated in our own preliminary trials in human skin with the same probe and pump and at the 
similar flow rate. When the experiment was finished, the probes were removed from the subjects’ 
arms. 
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Figure 4: Schematic of the experimental set-up. Arrows indicate: A – Distance between the cubital 
fossa and the BoNTA injection point (5cm); B – Capsaicin patch application covering probe 1 and 
2; C – Distance between probes inlet and outlet (3cm); D – Distance between probe 1 and 2 (1cm); 
E – BoNTA and saline injection point. Figure shows the schematic of the ROI of all interventions. 
BoNTA (10U) and control pre-treatment injections (E) were made approximately 5cm away from 
the cubital fossa (A). The guided needle was inserted across the skin for 3cm (C) for helping the 
insertion of the probes, which were inserted 1cm apart from each other (D), having the pre-treated 
site in the middle. The capsaicin patch was placed in a way to cover both probes (B). This figure 
was originally published in Pain Res Manage 2014;19(3):126-132 (104) and reproduced with 
permission from Pulsus Group Inc. 
7.2.7. Glutamate analysis 
Samples of approximately 10µL each were analyzed for their glutamate content to further 
investigate the glutamate changes over the time-course of the trial. ISCUSflex Microdialysis 
Analyzer (M Dialysis AB, Sweden) was used and through enzymatic reactions and colorimetric 
measurements can determine the content of different substances, including glutamate. The final 
results compare the glutamate concentration (in µM) between BoNTA and saline pre-treated sides. 
7.3. Study III 
7.3.1. Animals  
The study was performed using 20 adult male Wistar rats (2 to 4 months old) provided through the 
Animal Research Facility, Department of Pathology, Aalborg University Hospital, Denmark. 
Animals were housed in groups of three rats per cage, in temperature-controlled rooms, on a 12h 
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light/dark cycle with access to food and water ad libitum. All animals were deeply anesthetized and 
then euthanized prior to all experimental procedures.  
7.3.2. Primary cell culturing technique 
Primary cell cultures are broadly used to investigate in vitro neurobiological studies, which provide 
and enable further experimental investigation of cellular pathways, cell-cell interactions, besides 
physiology and morphology of the isolated cells. For the present study, animals were deeply 
anesthetized and euthanized by cervical dislocation before the initiation of the isolation. The 
trigeminal ganglia were exposed and carefully removed from the connective tissue and the rat 
skull. The isolated ganglia were then cut into smaller sections and after a number of steps, the 
trigeminal glial cell solution was added to uncoated culture flasks and then placed in the incubator 
(37°C - 95% air/ 5% CO2). The supplemented growth medium was changed after 3 and 24 hours in 
the first stage, and then continuously every 2 to 3 days prior to the experimental procedure. This 
isolation procedure has been standardized in previous studies (105). Whereas, the isolation of the 
glial cell from the neuron enables the investigation of specific issues, there is still incongruity that 
this procedure maintains its original function (97,106). It is hard to speculate how and to what level 
the responses form the isolated SGCs differ from the response of the whole TG, when the in vivo 
SGCs and neurons are intact. 
7.3.3. Immunohistochemistry (IHC) 
Immunohistochemistry is an important and largely used research and clinical tool to identify the 
distribution and localization of an antigen or a specific cellular element in the targeted tissue. The 
first step is to prepare the slides with sections of the tissue, followed by the staining and the 
interpretation of the results. The preparation of slides can be after the tissue has been fixed in 
formalin and embedded in paraffin or can be frozen and stored in -80°C. This is followed by the 
slicing of the tissue and placement of these slices to the slide. Then comes the staining itself that is 
based on the antigen-antibody binding reaction and can be a direct or indirect staining. In the direct 
one, the antigen binds to the antibody that is already conjugated with an enzyme for further 
detection. However, the indirect staining is the most commonly used and can be described in a few 
steps. Firstly, the specific antigen binds to the primary antibody, then after incubation with a 
secondary antibody that is conjugated with and enzyme, it binds to the primary one. In order to 
reveal the binding sites, a substrate is added to catalyze and generate the color to make the 
antigen visible. The slides are usually mounted after that to preserve the staining for further 
analysis. The last step is the interpretation of the staining under the appropriate microscope 
(107,108). For the present study, the TG was appropriately removed from the rat skull and treated 
to later be frozen in a cryo-mold. Each ganglion was sectioned in slices, of 10µm thickness, on a 
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cryostat and mounted on polysine coated glass slides. Then, the immunostaining was done by the 
indirect way, as described above. After incubation of primary and secondary antibodies, the slides 
were mounted with glass cover slips and images were obtained using a Nikon microscope (Az100, 
Nikon, Tokyo, Japan) equipped with a fluorescent illuminator (L200/D, Prior Scientific, Rockland, 
MA, USA) and a digital camera (DS-Vi1 Nikon, Tokyo, JP) connected to a personal computer. 
Image J was used for further analysis and noise-to-signal ratio adjustments. 
7.3.4. Immunocytochemistry (ICC) 
Immunocytochemistry is a common technique used as a laboratory tool to identify specific proteins 
or antigens in cell culture or suspension. Each kind of cell requires a slightly different procedure 
preparation in order to fix it to the slide and make it permeable for the antibodies. Basically, the 
cells need to be attached to the microscope slide that can already have adherent cells on them. 
After the fixation, the procedure is similar to the IHC explained above. Firstly, the slide will be 
incubated with the primary antibody, followed by the secondary one that has the conjugated 
enzyme and was treated with a substrate for the colorimetric enzyme reaction. Then, it will be 
mounted and interpreted under the appropriate microscope (109,110). For the present study, cells 
were fixed to the microscope slide and the procedure performed was exactly as just described 
above. After the staining was finished, the slides were mounted with glass cover slips. Images 
were obtained using a Nikon microscope (Az100, Nikon, Tokyo, Japan) equipped with a 
fluorescent illuminator (L200/D, Prior Scientific, Rockland, MA, USA) and a digital camera (DS-Vi1 
Nikon, Tokyo, JP) connected to a personal computer where the analysis and noise-to-signal ratio 
adjustments were completed. 
7.3.5. ELISA 
The enzyme-linked immunosorbent assay (ELISA) is an in vitro technique, which uses antibodies 
and change of color to identify and quantify an analyte, the substance being investigated. This 
technique works with a stationary solid phase that is usually on the bottom of the ELISA plate and 
this ligand will bind to the substance being analyzed, forming the antigen-antibody interaction. 
Depending on the type of ELISA technique being used, a detection enzyme will be linked to a 
primary or secondary antibody that will be bind to the antigen. After being in contact with the 
substrate, there will be a change of color that will be read by spectrophotometer, fluorometer, or 
luminometer (111,112). This technique can be either used to identify a substance, so a change of 
color will answer either yes or no, or to quantify the antigen, having the reading in the end. This is a 
well-established and straightforward technique; even though, few challenges can surface, like 
timing, number, and volume of samples. The volume is an important issue when considering 
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ELISA as an analytical tool, since kits usually ask for 50 or 100µL samples. Both experiments 
detailed below used an ELISA kit for the detection and quantification of glutamate. 
7.3.6. Time-dependent glutamate release by ionomycin 
One of the interests of this study was to investigate if the isolated SGCs would release glutamate.  
In order to follow that, ionomycin was used as a pharmacological tool to increase intracellular 
calcium levels, leading to glutamate release. In order to test its functionality, a time-dependent 
experiment was made with time-points at 4, 8, 12, and 30 minutes with one concentration of 
ionomycin (5µM). Once cell confluence was ≈ 90%, the supplemented growth medium was 
washed off and replaced with the glutamate-free Dulbecco’s Modified Essential Medium (DMEM) 
and left overnight in the incubator. The glutamate-free medium was an important step since 
glutamate was also the investigated substance. On the day of the experiment, after the medium 
was replaced by a fresh one, the cells were treated with ionomycin for all the specific time-points, 
and samples were collected. The glutamate concentrations in the collected samples were 
determined using a competitive immunoassay for quantitative determination of glutamate in 
biological samples (BA E-2300, Labor Diagnostika Nord, Nordhorn, D).  
7.3.7. Modulatory effect of BoNTA on glutamate release from cultured SGCs  
After testing the efficacy of ionomycin in releasing glutamate and finding the best time-point, 
BoNTA was used to investigate its modulatory effect in blocking the calcium dependent glutamate 
release stimulated by ionomycin. As soon as the cultured cells’ confluence reached ≈ 90%, the 
supplemented growth medium was washed off and replaced with the glutamate-free medium and 
left in the incubator overnight. The overnight medium was replaced with pre-treatment medium 
containing 0.1pM, 1pM, 10pM and 100pM of BoNTA (Botox, Allegan, CA, USA) or glutamate-free 
medium and placed in the incubator (37°C) for 24h. After that, the cultures were treated with 5µM 
ionomycin for ionomycin alone, glutamate-free medium for control and a mixture of 50µM BAPTA 
plus 5µM ionomycin for BAPTA as a positive control. BAPTA is a well-established positive control 
for BoNTA (113). Samples of the cultured medium were collected after 30 minutes of incubation. 
Glutamate concentrations in the collected samples were determined using a competitive 
immunoassay for quantitative determination of glutamate in biological samples (BA E-2300, Labor 
Diagnostika Nord, Nordhorn, D). After analyzing the results of the present study, a new interval 
could be investigated since 10pM showed no result and 100pM did. The optimal dose is always the 
lowest one that presents a positive effect without adverse effect. In order to check BoNTA’s 
blocking effect, it is also possible to quantitatively measure cleaved SNAPs (SNAP-25 and/or 
SNAP-23) using western blot technique. This was not performed due to time and technical issues, 
even though, it is valued information that requires further investigation.  
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8. Discussion 
The effect of BoNTA on glutamate release was undoubtedly the common aspect for all 
studies in this Ph.D. project. Glutamate is an excitatory amino-acid that is known to be involved in 
pain transmission, besides maintenance of pain and sensitization states both at the peripheral and 
central levels. Exogenous glutamate injected into the temporalis muscle efficiently evoked pain 
(study I) that was diminished by BoNTA pre-treatment. Endogenous interstitial levels of glutamate 
(induced by capsaicin in combination with heat) were also decreased by pre-treatment of BoNTA, 
as documented by real-time dermal microdialysis technique (study II). Besides, ionomycin-evoked 
calcium-dependent glutamate release was also blocked by pre-incubation of BoNTA and isolated 
SGCs from rats’ TG (study III). The next session discusses the main outcomes of the studies 
presented in this thesis. 
8.1. Glutamate release in association with pain 
For a long time, glutamate was mainly considered to be involved in the central processing 
of pain (19); however, studies have shown its contribution and importance to the peripheral pain 
transmission (21). Glutamate is stored in synaptic or neurotransmitter vesicles, and this property 
makes it a suitable target for BoNTA to possibly modulate its vesicular release. Vesicles containing 
neurotransmitters need a membrane protein to assist their attachment and further substance 
release. BoNTA is known to cleave selectively a protein (SNAP-25) that is a part of a functional 
protein complex (SNARE), responsible for attaching these neurotransmitters’ vesicles to the cell 
membrane (8,69,85). The three studies in this Ph.D. approached potential analgesic and 
antinociceptive properties of BoNTA from different angles. 
Glutamate injection in the temporalis muscle induced pain and increased vasomotor 
responses (study I). This result is in line with previous studies of several groups that have been 
confidently using this model for years (37,114). Glutamate, when injected intramuscularly, elicits 
pain that is partly mediated through peripheral NMDA, receptors located on small fibers in the 
peripheral tissues, e.g. skin and muscle (37,115). Besides, glutamate injection has been shown to 
sensitize the peripheral tissues under investigation (32,37); however, when it was injected to the 
temporalis muscle, no significant sensitization was found in the present project in comparison with 
saline. This might have been due to several reasons, e.g. high variations among the responders or 
the assessment technique, which will be discussed further in the next section. 
Capsaicin in combination with heat was able to provoke pain, besides increasing the 
vasomotor reactions in the skin. Capsaicin has been used as an efficient experimental pain model 
and several formulations are available containing different doses (e.g. up to 8%) and for different 
routes of administration (e.g. for injection or topical administration). When applied, capsaicin 
interacts with sensory C fibers through activation of TRPV1 receptors, causing a burning pain 
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response due to neuropeptides release, e.g. glutamate, CGRP, and SP (44,45). It is common to 
use injection and some topical formulations (116), but in this PhD project, for the first time, the 
clinically approved capsaicin patch (Qutenza, 8%) was used to elicit pain. Since there were no 
previous studies available to base our methodology, some pilot studies were conducted in order to 
reach a potent and yet stable pain model (item 9.1). The final model (capsaicin plus mild heat) 
yielded satisfactory and similar results as previous studies, in regard to pain and vasodilation 
(52,117,118), besides being effective in releasing glutamate.             
Recent evidences of non-neuronal cells being involved in pain transmission and 
maintenance (96,98) broaden the idea to investigate the release of glutamate from SGCs isolated 
from the TG of rats; this particular type of cells had not been studied before. The results were 
adequate, presenting a concentration-dependent glutamate release evoked by ionomycin, 
revealing a calcium-dependent mechanism. Previous studies in different types of glial cells had 
already successfully showed similar results (29,119,120). This study linked neuronal (study I) and 
non-neuronal (study III) aspects, both targeting peripheral cells innervated by the TG and their 
contribution to glutamate release and effect.   
Taken together, three models were successfully established with connections on 
pain/nociception and glutamate. Consequently, it was, then, possible to investigate BoNTA 
modulatory effect on these tissues and cells, together with glutamate release. The next topic of this 
thesis presents BoNTA’s effect on the above mentioned studies, with a focus on evidence and 
assumption of glutamate release and its blockade by BoNTA. 
8.2. Blockade of glutamate release by BoNTA 
BoNTA’s effect on pain and its modulation on glutamate release was the focus in this 
Ph.D. project. As already proposed, BoNTA selectively cleaves SNAP-25, a synaptosomal 
membrane protein that is part of a complex that enables vesicles containing neurotransmitters to 
attach and fuse to the pre-synaptic neuron membrane to further release of the substances. This 
mechanism has already been thoroughly studied in regard to acetylcholine and muscle contraction; 
however, it is not yet fully elucidated for other substances and tissues. There are also evidences 
showing that non-neuronal cells are involved in pain and neurotransmitter release and re-uptake. 
Hence, these cells might also express SNAP-25 and SNAP-23 (an analogue of SNAP-25) and a 
similar cleaving mechanism might be involved when BoNTA is exposed to those cells.  
The analgesic effect of BoNTA was investigated in both human studies (I and II). A 
number of direct and indirect approaches were used in order to follow the responses in glutamate 
release or modulation by treatment of BoNTA. The most prominent and direct finding came from 
the microdialysis study (study II), where a decreased level of glutamate was found in the BoNTA 
pre-treated site opposed to the control one. It is believed that BoNTA partly blocked the release 
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through the mechanism cited above. Even not having a direct evidence of glutamate or other 
substance blockade in study I, the decreased pain and reduced vasomotor responses are believed 
to result from BoNTA effect in blocking substances involved in pain and vasodilation, including 
glutamate, CGRP, and SP. There are still divergences about analgesic effect of BoNTA in 
particular in human experimental studies, with mostly positive results (71,80,121,122); however, 
negative outcomes have also been reported (92-94).  
Besides the studies showing transmitter release from neurons and the inhibitory effect of 
BoNTA, in study III, we aimed at cell-based platform of non-neuronal cells to investigate whether 
BoNTA can yield similar effects on vesicular release of substances from these cells. This is a new 
concept as there are only few evidences proposing that BoNTA moves from the peripheral site of 
application, e.g. muscles, and can reach the central nervous system via retrograde transportation. 
If this hypothesis is correct, then BoNTA can reach the sensory ganglia and can yield effects on 
non-neuronal cells to inhibit substance release, which are involved in sensory transmission and 
pain. In study III, besides the investigation of glutamate release blockade by BoNTA, the presence 
of SNAP-25 and SNAP-23 was also investigated to shed light of possible mechanisms involved. It 
was observed through IHC and ICC that SGCs present the SNAPs similar to neurons and that 
BoNTA was able to reduce the calcium-dependent vesicular glutamate release when stimulated by 
ionomycin. Since SNAP-23 was already shown to be present on astrocytes, we expected to find 
similarities with SGCs. However, besides SNAP-23, SNAP-25 was also identified both in the tissue 
of the TG and in the isolated cells, suggesting that BoNTA is able to modulate vesicular release of 
neurotransmitters, e.g. glutamate, both in neuronal or non-neuronal cells.  
Further investigation is needed to better elucidate other aspects, like the percentage and 
presence of the cleaved SNAPs. Retrograde transport of BoNTA needs further investigation at 
both molecular and basic pain models in animals. For a long time, it was believed that, when 
injected peripherally, BoNTA wouldn’t leave the injection site. However, evidences are showing 
central effects from peripherally treated BoNTA in animal and human studies, but there are still a 
huge amount of controversies and missing points, indicating the need of further research. Taken 
together, the studies in this Ph.D. project were designed to address one common ground in 
targeting glutamate at peripheral neuronal and non-neuronal pathways by BoNTA.  
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9. Methodological considerations and limitations 
This section presents some discussion aspects relating to the methodology that has not been 
discussed in the papers and should also be considered.    
9.1. Experimental models of pain 
Glutamate injection in the temporalis muscle of healthy humans was used in study I as the pain 
model, and it was effective to evoke reliable pain and vasomotor responses with no safety issues 
to be reported or recorded. It was also expected that the applied model would also sensitize the 
muscle tissue reflected on the mechanical sensitivity to pressure being higher after glutamate, 
according to previous studies (38,123). However, this was not found in study I, becoming irrelevant 
to investigate any potential effects of BoNTA on muscle sensitization. It can be suggested that the 
assessment technique was not the ideal one, considering the targeted tissue. This is discussed 
further in item 9.4. The experimental pain model used in study II was a capsaicin patch in 
combination with heat (40°C) after an acute sensitization period (45°C/5 min). Even though the 
expected response was successfully achieved with the above mentioned model, a number of 
experimental pilots were done. To elicit pain, a capsaicin solution of 1% was used in a small 
chamber that only caused a small flare. At that time, the patch had just been approved to treat 
peripheral neuropathy and no record was found for its use as a potential inducer for an 
experimental pain model in humans. It is well known that single application of capsaicin evokes 
burning sensation and pain due to release of neurotransmitters contributing in pain pathways. 
However, repeated applications cause desensitization of sensory and mechanical nerve cells and 
result in pain relief (49). This dual effect makes capsaicin an ideal substance for studying pain as a 
model. A pilot study was performed with the application of the patch alone, but still the results were 
not satisfactory in terms of pain induction or vasomotor responses. It was noticed that some 
subjects did not react at all to the capsaicin patch and the search for a more stable, stronger, but 
yet not unbearable stimulation was continued until we tested the pre-sensitization stimulation with 
heat application on top of the capsaicin patch, resulting in the used pain model for study II. 
9.2. BoNTA 
BoNTA injections were always performed at the hospital by the neurologist responsible for the 
studies. For study I, the exact point of injection was determined through palpation of the contracted 
temporalis muscle after jaw clenching. This had to match a part of the temporalis muscle without 
hair for later observation of vasomotor changes. This means that it needed to be the anterior part, 
where the muscle is thinner. A careful analysis of the intended injection area was made in order to 
avoid the frontal branch of the superficial temporal vein. In study II, the intradermal injection of 
BoNTA was chosen, because studies show that pain relief occurs prior to muscle paralysis (91), 
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when injected in the muscle. In a tentative way to exclude this co-founding factor that occurs in the 
muscle, the skin was selected. The forearm skin was selected because it was easily accessible 
compared with the facial dermis, and the forearm in humans has been subjected to many pain 
studies and somewhat it is a standard site. Besides, a careful training was taken in order to ensure 
that the injections, and later on the probes, were applied in the dermis layer of the skin, which is 
where the capillaries and nerve endings are present and, consequently, where the 
neurotransmitters are released. 
9.3. Pain assessments 
Besides VAS and the mapping of pain area distribution, there are a number of other techniques 
that can be used, and one of them is the McGill Pain Questionnaire (MPQ), a broadly used and 
reliable technique where patients and subjects choose words in order to characterize their pain by 
aids of word descriptors (124). MPQ was not used in these studies due to methodological issues, 
but it could be included when designing a study. Besides, considering that pain is a subjective 
measurement, it is a good idea to match subjective measurements (VAS, MPQ) with objective 
ones (thermo-imaging, LDI, FLPI).  
9.4. Pressure pain threshold 
Pressure algometry is a technique that is non-invasive and easy to apply; however, one of the 
main disadvantages of this method is high variability in responses, even though each person can 
be normalized to his/her own baseline assessments. When assessing the sensitivity changes in 
the muscle, we cannot exclude the skin influence in the result and net pressure in the muscle 
(125). The location can also influence the assessment and make the inter individual and intra 
individual variation higher, confounding the results. Another device called palpometer can be used 
to detect the mechanical sensitivity. The palpometer consists of a small plastic cylinder with a 
probe in the tip that is calibrated to a specific pressure load to be delivered to the tissue and detect 
its sensitivity (126,127). The hand-held algometer has been shown to work in research settings, 
even though there are still issues about high variations, calibration issues, and the need for a 
power supply. In comparison, the palpometer was developed to be an easy-to-use, low-cost, and 
purely mechanical device.  
9.5. Vasomotor response assessments 
This section includes methodological considerations not covered in papers for the techniques 
thermography and blood flow assessments in both studies I and II. All measurements were done in 
a standardized manner, to ensure an optimal room temperature and lightning in order to decrease 
any influence in the results. Subjects were asked to refrain from exhausting activities, caffeine 
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and/or drinks, and alcohol for at least 24h prior to the experiment; these are all well-known 
activities and substances that increase the skin blood perfusion and temperature, causing flushes 
especially in the neck and face area (128). Besides, on the day of the experiment, the study 
participants were allowed - at least 15 minutes before the start - to adapt to the lab environment. 
Moreover, a supine position was ensured in order to decrease the body heat loss (129). Other 
important factors were the distance between devices and tissue and the definition a region of 
interest (ROI). The distance between the camera lenses and the tissue to be assessed determines 
the area that will be captured. The longer the distance, the larger will be the portion of the tissue 
assessed, and after finding the optimal distance, it was kept constant for all participants. The ROI 
was also defined for each measurement and used to provide a more precise and localized 
information on the changes. These adjustments can provide the opportunity to see the temporal 
profile of the changes as well as the confined changes right in the treatment site. Measurements 
were performed over time after each injection. In the presented studies, the same thermocamera 
was used; however, two different devices to assess the blood flow were used. LDI is a 
sophisticated and well-stablished scanning technique for non-invasive monitoring of microvascular 
perfusion often referred to as microvascular blood flow or red blood cell flux (101,103). This 
technique enables a real time measurement of the moving red blood cells inside the vessels, like 
arterioles and veins, in the dermis. Alternatively, Laser Doppler Flowmetry (LDF) and full field laser 
technique can also be used to follow the real time assessment of changes in blood flow. However, 
LDF is based on a single point measurement and the probe needs to be in contact with the skin 
and sometimes it’s hard to interpret, due to a great variability and changes in one single point 
(130). This technique is also used in clinical settings to assess skin inflammation, vascular 
disorders, and to follow burns and wound healing processes (131,132). FLPI is another possibility 
that captures the whole area in one single shot, allowing very rapid changes to be followed. When 
comparing both devices used, FLPI and LDI, they are easy to use, fast and reliable. However, FLPI 
can be advantageous if the purpose is to follow rapid changes in the vasomotor response since it 
can take one frame per second that covers a large area. On the other hand, LDI can take from few 
seconds to minutes to scan the intended area. 
9.6. Microdialysis 
Microdialysis technique was used in study II and many issues that should be considered are 
presented here. The microdialysis membrane that is inserted in the targeted tissue acts as an 
"artificial blood vessel", which means that it is permeable to fluids and substances. The 
concentration gradient is what governs the direction of migration of the targeted substances to and 
from the membrane lumen and the interstitial space where the microdialysis probe is inserted. At 
the same time that these substances move through this membrane and tissue, a sample is taken 
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at the end of the cannula. It is through these fluid samples that one can measure the level of many 
substances if a reliable measurement technique is available. Figure 5 shows in details how the 
mechanism of the diffusion of molecules works.  
 
Figure 5: A linear microdialysis membrane is inserted into the dermis layer of the skin with the help 
of a needle that is removed afterwards. The membrane is attached to a microdialysis pump, which 
drives a perfusate solution through the cannula in a chosen perfusion rate. When the perfusate 
reaches the permeable membrane, substances and fluid, driven by the concentration gradient, run 
freely from the lumen of the membrane and the interstitial space. At the same time that this 
exchange is happening, the perfusate solution is running from one end (pump) to the other end, 
where a sample is collected in a vial. After collection of the sample, it can be stored and analyzed 
for the targeted substance. Reproduced from (133) with permission from Elsevier. 
This technique has been extensively used in the clinic as well as in the experimental field, from 
peripheral tissues, like the skin, to deeper muscles, organs, and brain (134-137). It is a valuable 
and flexible tool that can be used for a short period of time, similar to what was used in study III (5 
hours), but it can also be used for a longer period. It is also common to be used to track patients 
before and after surgery, in order to monitor the levels of different biomarkers to better follow 
patients’ recovery (138,139). Microdialysis is also thoroughly used in drug development and dose 
response studies to follow the pharmacokinetics and pharmacodynamics of a specific drug 
(137,140). When setting up a microdialysis experiment, besides finding the appropriate 
measurement technique, many other aspects need to be taken in consideration, such as:  
 Type of membrane – a linear flexible probe might be suitable for peripheral tissues, like skin 
or muscle, while a stiff probe is needed for a brain microdialysis; 
 Length of membrane – a longer membrane enables a better recovery of the substances, 
however, this will be evaluated in accordance with the size of the targeted tissue;  
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 Membrane cut-off – this will determine which substances will be recovered. For instance, 
the molecular weight of the targeted substance to be collected needs to be smaller than the 
membrane cut-off;  
 Targeted tissue – the location of the tissue will influence the accessibility and the technique 
for the probe insertion, in order to maintain its optimal function – some probes are really 
fragile and any inadequate procedure might damage the probe;  
 Perfusion flow – a high flow will remove or introduce as many molecules as possible, 
whereas a low flow will have a more concentrated dialysate and will not disturb the 
physiology of the tissue as much as a high flow. The chosen flow will also influence the 
volume of the dialysate; the lower the perfusion rate, the lesser the sample volume is. 
In study II, microdialysis was used to monitor continuous changes over time for the interstitial 
glutamate level in a dynamic way to follow the analgesic effect of BoNTA on the pattern of 
glutamate concentration, after challenging the tissue with the capsaicin + mild heat pain model. 
This method was chosen because it has the capacity to show small and localized changes, since 
the probes are placed right below the stimulated area. It is likely that such small and localized 
changes in the glutamate release, for example, wouldn’t reach the systemic blood circulation, 
disabling the possibility of following the changes through blood samples. Since the probe insertion 
is not a painless procedure and does cause damage to the tissue, some experiments tend to use 
topical anesthetic before its insertion (141). Since the main objective of study II experiment was to 
follow the glutamate level changes, a substance involved in pain sensation and transmission, we 
chose to use only an ice pack for 5 minutes to cause transient numbness in the skin to decrease 
the potential pain due to probe insertion. The length of the used membrane was 10mm and the 
size also interferes on the recovery of the substances; a longer probe will recover more molecules 
(136,142). Because of the insertion procedure and the available area in the forearm, a longer 
probe could not have been used. When inserting the membrane, 1cm was left on each side to 
better accommodate the membrane and also to allow more space to apply the pain model in order 
to avoid the in- and out-lets of the probe insertion.  Sample volume was one of the limitations of 
this study since we had small volume samples and more sophisticated and sensitive tool, as 
High Performance Liquid Chromatography (HPLC) was not available. However, the analytical tool 
used needs to match the acquired volume. Considering this, the volume of the sample and the 
analytical tool also influence how many substances can be analyzed for the same experiment. In 
order to increase the volume, several membranes and pumps can be used simultaneously or the 
perfusion rate can be enhanced. However, if the rate is too high, it may not allow the molecules to 
reach the equilibrium with the tissue and the sample will be unsuitable. 
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9.7. Primary cell culture 
For study III, some methodological issues can be outlined. Ionomycin was the pharmacological tool 
used to promote calcium-dependent glutamate release from the SGCs culture. Besides ionomycin, 
other substances like bradykinin (28), PGE2 (143), and ATP (144) could be used for the same 
purpose. Ionomycin was chosen due to the positive outcomes in previous studies in astrocytes, 
where they also showed a time-dependent response (29). Another concern was the maintenance 
of the characteristics of the studied SGCs, since they were removed from the sensory ganglia 
where they surround neurons and interfere in their response. The knowledge about this close and 
complex interaction between neurons and glial cells is very limited and it is also hard to predict how 
similarly the response from the in vitro studies to the in vivo tissue is. However, we were able to 
show that expression of the SNAPs remained unchanged in the tissue and in isolated cells. A 
study made by Poulsen and colleagues analyzed these isolated SGCs up to 21 days of in vitro 
culture and concluded that this method can be a valid and useful cell-based platform for studying 
glial activity and modulation (105). The same procedures were followed in study III. Besides the 
mentioned results and methodological issues discussed above, there are other considerations that 
could further enrich this study. Providing results on the ability of BoNTA to cleave SNAPs would be 
highly relevant. BoNTA ability to cleave SNAP-25 has already been demonstrated in astrocytes by 
immunocytochemistry after retrograde transport of BoNTA in the spinal cord. Therefore, additional 
experiments could be performed in order to investigate whether cl-SNAP-25 and 23 can be found 
in the trigeminal satellite glial cells. Besides, the percentage of the expression and cleavage is also 
highly important. The condition under which the inhibitory effects of BoNTA occur should also be 
addressed. There are a couple of important factors: type of the toxin, treated cells (type, age, etc), 
concentration, and time of the toxin incubation. The presented result from the toxin modulation 
seemed to have a possible effect of “all or nothing”. It seems that low doses of toxin provide full 
analgesic effects (from the lowest effective dose), without any motor effects. For example, at 3 
U/kg, BoNTA seems not to affect the carrageenan- and capsaicin-evoked pain, but at slightly 
higher dose (3.5 U/kg), and further increased doses (5 and 7 U/kg) BoNTA exerts similar and 
maximal analgesic activity (80). Similar antinociceptive effect of 3.5, 7, and 15 U/kg BoNTA doses 
was reported in formalin test (88). In few studies, increased analgesic effects have been shown to 
occur at higher doses of the applied toxin (20–40 U/kg) (60,88). However, systemic spread of 
BoNTA impaired the animal motor performance, which most likely interfered with the ability to 
produce a nocifensive reaction (88). Up until now, clinical trials have not addressed a clear dose-
response of BoNTA, and the employed doses are based on the clinical effect, only empirically 
(145). These unanswered questions can help elucidate and better describe the 
antinociceptive/analgesic effects of the toxin at the level of sensory ganglia.  
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10. Conclusions and future perspective 
This Ph.D. project provided both direct and indirect evidence of potential mechanisms 
underlying analgesic/antinociceptive effects of BoNTA by modulatory effect on glutamate release. 
For the first time in humans, an analgesic effect within hours after BoNTA treatment was shown. 
Another novelty was the use of the microdialysis technique in humans to dynamically and directly 
show a decrease in evoked glutamate levels following administration of BoNTA. Hence, it was also 
presented for the first time that BoNTA can modulate the vesicular release of glutamate from non-
neuronal cells of the trigeminal ganglia in the peripheral nervous system, and that this effect was 
concentration-dependent and most likely through cleavage of SNAPs. It was concluded that 
BoNTA exerts its analgesic effect, somehow, through modulation of glutamate.  
Outcome from these three studies shed light on potential mechanism of action of BoNTA 
for pain relief and also advanced the understanding on potential contribution of SGCs in 
nociception. The effect of BoNTA on glutamate release was the common point over the studies in 
this Ph.D. project and it is proposed that BoNTA, at least in part, blocks or reduces the release of 
glutamate, which is one of the potential players in pain pathways. Even though glutamate was the 
main neurotransmitter investigated, other pain mediators should also be considered and 
investigated deeper. And yet, much is still unknown about the antinociceptive and analgesic effects 
of BoNTA, indicating a need for further research to better expand its benefits in a safe and reliable 
approach. Increasing the evidences on BoNTA antinociceptive mechanism can facilitate its 
approval for other painful conditions in addition to migraine. Brain imaging techniques, advanced 
methodology in in vivo animal studies, investigation of other substances involved in pain by means 
of microdialysis technique and translational studies in patients are some of the prospective studies 
that could assist in expanding our knowledge.  
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